Operating Lease, Right-of-Use Asset of Cerevel Therapeutics Holdings, Inc. from 31 Dec 2019 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2019 to 31 Mar 2024.
  • Cerevel Therapeutics Holdings, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 31 Mar 2024 was $19,667,000, a 8.2% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Cerevel Therapeutics Holdings, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $19,667,000 -$1,767,000 -8.2% 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $20,125,000 -$1,695,000 -7.8% 31 Dec 2023 10-Q 08 May 2024 2024 Q1
Q3 2023 $20,580,000 -$1,624,000 -7.3% 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 $21,016,000 -$1,557,000 -6.9% 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $21,434,000 -$1,493,000 -6.5% 31 Mar 2023 10-Q 03 May 2023 2023 Q1
Q4 2022 $21,820,000 -$1,431,000 -6.2% 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $22,204,000 -$1,372,000 -5.8% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $22,573,000 -$1,315,000 -5.5% 30 Jun 2022 10-Q 01 Aug 2022 2022 Q2
Q1 2022 $22,927,000 -$1,260,000 -5.2% 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $23,251,000 -$1,208,000 -4.9% 31 Dec 2021 10-K 22 Feb 2023 2022 FY
Q3 2021 $23,576,000 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $23,888,000 30 Jun 2021 10-Q 11 Aug 2021 2021 Q2
Q1 2021 $24,187,000 31 Mar 2021 10-Q 17 May 2021 2021 Q1
Q4 2020 $24,459,000 -$1,556,000 -6% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q4 2019 $26,015,000 31 Dec 2019 10-K 24 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.